Oct. 2 at 10:50 AM
$TCRX Checkpoint Capital L.P. raised its holdings in TScan Therapeutics by 14.9%, now owning 2,017,650 shares valued at approximately
$2.78 million, making it the firm's 10th largest investment.
Institutional ownership is significant, with 82.83% of TScan Therapeutics shares held by institutions and hedge funds, indicating strong support from large investors.
Analysts have mixed outlooks on the stock, with a consensus rating of "Buy" and a price target range from
$7.00 to
$10.00, suggesting potential upside despite recent market volatility.
